Skip to main content

AML

AML

Criteria to qualify for study: Drug used in study:
  • Must refuse or not be a candidate for intensive induction chemo.
  • Previously treated subjects should have evidence of persistent or recurrent AML

HEMREF 48 - H3B-8800-101 H3 Biomedicine and Eisai

An Open-Label Multicenter Phase I trial to evaluate the Safety, Pharmacokynetics and Pharmacodynamic of Splicing Modulator H3B-800 for Subjects with AML.

Criteria to qualify for study: Drug used in study:
  • Phase 1: Subjects with confirmed relapsed or refractory
  • AML with a documented FLT3 and/or Ras mutation, or age ≥ 60 years with newly diagnosed FLT3+ and/or Ras+ AML and not eligible for standard induction chemotherapy, or FLT3+ and/or Ras+, high-risk MDS/CMML (defined as ≥ 10% peripheral blood or marrow blasts and International Prognostic Scoring System [IPSS] score ≥ 2) and relapsed or refractory to prior therapy
    Phase 2: Subjects with confirmed relapsed or refractory AML with a documented FLT3 and/or Ras mutation, or age ≥ 60 years with newly diagnosed FLT3+ and/or Ras+ AML and not eligible for standard induction chemotherapy

AML29 BSC-101-01 Strategia Therapeutics

A Phase 1/2a study of E6201 for the treatment of advanced hematologic malignancies with FLT3 and or Ras mutations, including Acute Myeloid Leukemia (AML), Myelodysplastic syndrome (MDS) or Chronic myelomonocytic leukemia (CMML)

Criteria to qualify for study: Drug used in study:
  • Patients must achieved a 1st or 2nd CR or CRI /
  • Have adverse risk disease or AML for which there is othewise a substantial risk of relapse / albumin > 3.2 / bili < 1.5

AML 27 SCRI Stemline Therapeutics, STML401-0214

A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients with Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease in First CR